Health Care Supplies

Volitionrx

Volitionrx released FY2026 Q1 earnings on May 14 Pre-Market EST, actual revenue USD 985.08 K (forecast USD 409.92 K), actual EPS USD -0.97 (forecast USD -0.73)

Volitionrx to Release FY2026 Q1 Earnings on May 15, Pre-Market EST; Forecast Revenue USD 409.92 K, EPS USD -0.73

Volitionrx released FY2025 earnings on March 31 Pre-Market (EST), actual revenue USD 1.727 M (forecast USD 1.821 M), actual EPS USD -4.3726 (forecast USD -4.2)

Volitionrx released FY2025 Q4 earnings on March 31 Pre-Market (EST), actual revenue USD 447.03 K (forecast USD 753.51 K), actual EPS USD -0.0518 (forecast USD -0.0416)

Volitionrx to Release FY2025 Earnings on April 1, Pre-Market EST; Forecast Revenue USD 1.821 M, EPS USD -0.21

VolitionRx Ltd. Releases Capture-Seq Liquid Biopsy Method

Volitionrx released FY2025 Q3 earnings on November 13 Pre-Market (EST), actual revenue USD 627.28 K (forecast USD 715.59 K), actual EPS USD -0.994 (forecast USD -0.8857)

Volitionrx released FY2025 9 Months Earnings on November 13 Pre-Market (EST), Actual Revenue USD 1.28 M, Actual EPS USD -3.342

VolitionRx Limited to Release Third Quarter 2025 Financial Results

Volitionrx to Release FY2025 Q3 Earnings on November 14 Pre-Market EST, Forecast Revenue USD 715.59 K, EPS USD -0.0442

VolitionRX Ltd. Sponsors GenomeWeb Webinar to Showcase Nu.Q® Discover Service

Volitionrx released FY2025 Q2 earnings on August 14 Pre-Market (EST), actual revenue USD 406.69 K (forecast USD 375.72 K), actual EPS USD -1.2243 (forecast USD -0.9714)

Volitionrx released FY2025 Semi-Annual earnings on August 14 Pre-Market (EST), actual revenue USD 653.07K, actual EPS USD -2.3506

Volitionrx to Release FY2025 Q2 Earnings on August 15 Pre-Market EST, Forecast Revenue USD 375.72K, EPS USD -0.0485

D. Boral Capital Reiterates Buy Rating on VolitionRx

VolitionRx Limited's Nu.Q® Discover project makes significant progress

VolitionRX Updates Cancer Screening and Monitoring Strategies

VolitionRX CEO Acquires Company's Common Stock

VolitionRX Announces NU.Q® H3.1 Concentration Linked to Sepsis and Organ Failure

VolitionRx Announces Nu.Q Veterinary Cancer Test in Thailand

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

VNRX

VolitionRX (AMEX:VNRX) reported Q1 2026 earnings with revenue of approximately $1 million, up from $0.2 million in Q1 2025, driven by a new Q Vet agreement. Operating expenses rose to $6.3 million, influenced by severance costs and increased R&D. The company is advancing its veterinary products and NUQ NETS platform, preparing for clinical use in lung cancer management, and pursuing licensing agreements with diagnostic firms.

benzinga_article

Full Transcript: VolitionRX Q1 2026 Earnings Call

Earnings Watch

Volitionrx | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1 M

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update | VNRX Stock News

StockTitan

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update | VNRX Stock News

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update | VNRX Stock News

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update | VNRX Stock News

VolitionRx Limited has submitted a clinical manuscript for peer review regarding its Nu.Q® Vet Feline prototype assay, which accurately detects lymphoma in cats with 97% specificity. This breakthrough could unlock a $5 million milestone payment and addresses a significant need in veterinary medicine. The company aims to make cancer screening routine for pets, with the feline test expected to double its market potential. The North American veterinary oncology market is projected to reach $1.77 billion by 2025, with increasing awareness and focus on feline treatments driving growth.

prnewswire

08:17 ETVolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

Volitionrx(VNRX.US)

Full Transcript: VolitionRX Q1 2026 Earnings Call

Volitionrx | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1 M

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update | VNRX Stock News

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update | VNRX Stock News

08:17 ETVolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats